triazolam has been researched along with Gelineau Syndrome in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Studies of long-term administration of triazolam are required to determine if the improvement of nocturnal sleep is maintained." | 2.67 | Short-term triazolam use improves nocturnal sleep of narcoleptics. ( Aloe, FS; Ledereich, PS; Snyder, M; Starz, KE; Thorpy, MJ, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thorpy, MJ | 1 |
| Snyder, M | 1 |
| Aloe, FS | 1 |
| Ledereich, PS | 1 |
| Starz, KE | 1 |
1 trial available for triazolam and Gelineau Syndrome
| Article | Year |
|---|---|
Short-term triazolam use improves nocturnal sleep of narcoleptics.
Topics: Adult; Arousal; Circadian Rhythm; Drug Administration Schedule; Female; Humans; Male; Middle Aged; N | 1992 |